β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features.
Park S, Park JM, Park M, Ko D, Kim S, Seo J, Nam KD, Jung E, Farrand L, Kim YJ, Kim JY, Seo JH.
Park S, et al. Among authors: kim jy, kim yj, kim s.
Cancer Cell Int. 2022 Sep 20;22(1):289. doi: 10.1186/s12935-022-02713-9.
Cancer Cell Int. 2022.
PMID: 36127671
Free PMC article.